# FDA recall D-1302-2022

> **Teva Pharmaceuticals USA Inc** · Class II · drug recall initiated 2022-07-21.

## Product

Matzim LA (Diltiazem Hydrochloride) Extended-Release Tablets, 180 mg, 30-count bottle, Rx Only, Manufactured by: Actavis Laboratories FL, Inc., Fort Lauderdale, FL 33314, USA; Distributed by: Actavis Pharma, Inc., Parsippany, NJ 07054, USA; NDC 52544-691-30.

## Reason for recall

Failed Dissolution Specifications: below specification limits for dissolution.

## Distribution

Nationwide in the USA and Puerto Rico

## Key facts

- **Recall number:** D-1302-2022
- **Recalling firm:** Teva Pharmaceuticals USA Inc
- **Classification:** Class II
- **Product type:** drug
- **Status:** Terminated
- **Initiation date:** 2022-07-21
- **Report date:** 2022-08-10
- **Termination date:** 2023-04-18

- **Voluntary/Mandated:** Voluntary: Firm initiated
- **Location:** Parsippany, NJ, United States

## Primary source

FDA Enforcement Reports: https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-1302-2022

## Citation

> AI Analytics. FDA recall D-1302-2022. Retrieved 2026-06-25 from https://api.ai-analytics.org/recall/D-1302-2022. Source: US FDA. Licensed CC0.

---

*[Dataset catalog](/datasets/) · [FDA recalls dataset](/datasets/fda-recalls) · CC0 1.0*